Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $890.60 Consensus Target Price from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average rating of “Moderate Buy” from the twenty-six brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $890.60.

A number of equities research analysts have issued reports on the stock. UBS Group cut their price target on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Guggenheim lowered their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating for the company in a research report on Thursday, May 1st. Finally, JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. Park Avenue Securities LLC raised its stake in Regeneron Pharmaceuticals by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 2,019 shares of the biopharmaceutical company’s stock valued at $1,438,000 after buying an additional 130 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 3,106 shares of the biopharmaceutical company’s stock valued at $2,212,000 after purchasing an additional 99 shares during the last quarter. Fermata Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $207,000. Merit Financial Group LLC grew its position in Regeneron Pharmaceuticals by 8.9% during the 4th quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company’s stock valued at $618,000 after purchasing an additional 71 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management grew its position in Regeneron Pharmaceuticals by 154.8% during the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,147 shares of the biopharmaceutical company’s stock valued at $2,242,000 after purchasing an additional 1,912 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $614.79 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The stock has a 50 day moving average price of $596.79 and a two-hundred day moving average price of $679.72. The company has a market capitalization of $66.38 billion, a P/E ratio of 16.06, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.55 earnings per share. Analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.